⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ACET News
Adicet Bio, Inc. Common Stock
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
businesswire.com
ACET
Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
businesswire.com
ACET
Adicet Bio Announces Reverse Stock Split
businesswire.com
ACET
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
businesswire.com
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
ACET
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2 nd Annual Healthcare Innovation Conference
businesswire.com
ACET
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
businesswire.com
ACET
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
businesswire.com
ACET
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
businesswire.com
ACET
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
ACET